NASDAQ:CBIO - Catalyst Biosciences Stock Price, Price Target & More

$27.74 +0.07 (+0.25 %)
(As of 04/19/2018 11:30 AM ET)
Previous Close$27.67
Today's Range$26.89 - $27.98
52-Week Range$3.11 - $37.00
Volume28,242 shs
Average Volume387,930 shs
Market Capitalization$315.18 million
P/E Ratio-3.72
Dividend YieldN/A
Beta2.52

About Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences logoCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. The company also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has a strategic collaboration with Mosaic Biosciences to develop anti-C3 protease assets for dry age-related macular degeneration and other serious inflammatory retinal disorders. The company is headquartered in South San Francisco, California.

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-266-8674

Debt

Debt-to-Equity RatioN/A
Current Ratio4.48%
Quick Ratio4.48%

Price-To-Earnings

Trailing P/E Ratio-3.72
Forward P/E Ratio-6.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.02 million
Price / Sales323.36
Cash FlowN/A
Price / CashN/A
Book Value$5.29 per share
Price / Book5.24

Profitability

EPS (Most Recent Fiscal Year)($7.45)
Net Income$-21,560,000.00
Net Margins-2,117.98%
Return on Equity-86.40%
Return on Assets-60.48%

Miscellaneous

Employees13
Outstanding Shares11,890,000

How to Become a New Pot Stock Millionaire

Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences's stock reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences (NASDAQ:CBIO) announced its earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.41) by $0.45. The biopharmaceutical company earned $0.32 million during the quarter, compared to the consensus estimate of $0.23 million. Catalyst Biosciences had a negative return on equity of 86.40% and a negative net margin of 2,117.98%. View Catalyst Biosciences' Earnings History.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Catalyst Biosciences.

What price target have analysts set for CBIO?

3 Wall Street analysts have issued 12 month price targets for Catalyst Biosciences' shares. Their forecasts range from $11.00 to $75.00. On average, they anticipate Catalyst Biosciences' stock price to reach $45.00 in the next year. View Analyst Ratings for Catalyst Biosciences.

Who are some of Catalyst Biosciences' key competitors?

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the folowing people:
  • Dr. Nassim Usman Ph.D., Chief Exec. Officer, Pres and Director (Age 58)
  • Mr. Fletcher Payne, Chief Financial Officer (Age 55)
  • Dr. Howard Levy M.B.B.Ch., Ph.D., M.M.M., Chief Medical Officer (Age 64)
  • Dr. Charles S. Craik Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Dr. Jack Nguyen Ph.D., Co-Founder

Has Catalyst Biosciences been receiving favorable news coverage?

Media stories about CBIO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalyst Biosciences earned a media sentiment score of 0.22 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.01 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $27.74.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $315.18 million and generates $1.02 million in revenue each year. The biopharmaceutical company earns $-21,560,000.00 in net income (profit) each year or ($7.45) on an earnings per share basis. Catalyst Biosciences employs 13 workers across the globe.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-8674 or via email at [email protected]


MarketBeat Community Rating for Catalyst Biosciences (CBIO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Catalyst Biosciences (NASDAQ:CBIO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Catalyst Biosciences in the last 12 months. Their average twelve-month price target is $45.00, suggesting that the stock has a possible upside of 62.22%. The high price target for CBIO is $75.00 and the low price target for CBIO is $11.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $45.00$45.00$13.3333$10.50
Price Target Upside: 62.22% upside71.04% upside27.11% upside144.76% upside

Catalyst Biosciences (NASDAQ:CBIO) Consensus Price Target History

Price Target History for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ:CBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018B. RileySet Price TargetBuy -> Buy$19.00 -> $49.00HighView Rating Details
2/9/2018Chardan CapitalBoost Price TargetBuy -> Buy$10.00 -> $75.00HighView Rating Details
6/6/2017Ladenburg ThalmannInitiated CoverageBuy -> Buy$11.00LowView Rating Details
10/6/2016HC WainwrightReiterated RatingBuy$52.50N/AView Rating Details
6/30/2016Rodman & RenshawInitiated CoverageBuy$52.50N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Catalyst Biosciences (NASDAQ:CBIO) Earnings History and Estimates Chart

Earnings by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ:CBIO) Earnings Estimates

2018 EPS Consensus Estimate: ($5.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.30)($1.30)($1.30)
Q2 20181($1.32)($1.32)($1.32)
Q3 20181($1.42)($1.42)($1.42)
Q4 20181($1.50)($1.50)($1.50)

Catalyst Biosciences (NASDAQ CBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($1.15)N/AView Earnings Details
3/1/2018Q4 2017($1.41)($0.96)$0.23 million$0.32 millionViewN/AView Earnings Details
11/2/2017Q3 2017($1.34)$0.32 millionViewN/AView Earnings Details
8/3/20176/30/2017($1.46)($2.53)$0.11 millionViewN/AView Earnings Details
5/11/20173/31/2017($5.14)($4.57)$0.27 millionViewN/AView Earnings Details
3/8/201712/31/2016($5.63)($4.68)$0.10 million$0.10 millionViewN/AView Earnings Details
11/3/2016Q3($0.46)($0.40)$0.10 million$0.11 millionViewN/AView Earnings Details
8/4/2016Q216($0.31)($0.42)$0.10 million$0.11 millionViewN/AView Earnings Details
5/5/2016Q1 2016($4.65)$0.11 millionViewN/AView Earnings Details
7/31/2015Q2 2015($10.49)ViewN/AView Earnings Details
5/7/2015Q1 2015($20.98)$0.06 millionViewN/AView Earnings Details
11/5/2014Q314($0.22)($0.14)$0.03 millionViewListenView Earnings Details
8/6/2014Q214($0.33)($0.24)$0.04 millionViewListenView Earnings Details
5/7/2014Q114($0.37)($0.44)$3.54 million$0.0870 millionViewListenView Earnings Details
2/13/2014Q413($0.39)($0.40)$0.59 million$0.0930 millionViewListenView Earnings Details
11/5/2013Q3 2013($40.92)($39.87)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.37)($0.37)$0.35 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.34)($0.24)$600.00 million$3.54 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.31)($0.47)$0.83 million$0.59 millionViewListenView Earnings Details
11/6/2012Q312($0.39)($0.24)$0.87 million$0.77 millionViewN/AView Earnings Details
8/7/2012$0.39$0.43ViewN/AView Earnings Details
5/3/2012($0.25)$0.07ViewN/AView Earnings Details
2/21/2012($0.30)($0.29)ViewN/AView Earnings Details
11/1/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011Q2 2011($22.03)($7.66)ViewN/AView Earnings Details
5/5/2011Q1 2011($14.69)$43.44ViewN/AView Earnings Details
2/10/2011Q4 2010($2.10)($7.97)ViewN/AView Earnings Details
11/4/2010Q3 2010($1.05)$8.39ViewN/AView Earnings Details
8/4/2010Q2 2010$22.03$13.11ViewN/AView Earnings Details
5/5/2010Q1 2010$15.74$24.45ViewN/AView Earnings Details
2/11/2010Q4 2009($36.72)($100.82)ViewN/AView Earnings Details
11/5/2009Q3 2009($12.59)$5.25ViewN/AView Earnings Details
8/5/2009Q2 2009($33.57)($40.92)ViewN/AView Earnings Details
5/11/2009Q1 2009($32.52)($19.93)ViewN/AView Earnings Details
2/12/2009Q4 2008($34.62)($22.77)ViewN/AView Earnings Details
11/6/2008Q3 2008($45.11)($32.21)ViewN/AView Earnings Details
8/5/2008Q2 2008($36.72)($28.64)ViewN/AView Earnings Details
5/6/2008Q1 2008($37.77)($25.49)ViewN/AView Earnings Details
2/12/2008Q4 2007($32.52)($39.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Catalyst Biosciences (NASDAQ:CBIO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2015$0.56868/12/20158/14/20158/19/2015
(Data available from 1/1/2013 forward)

Insider Trades

Catalyst Biosciences (NASDAQ CBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 24.41%
Insider Trading History for Catalyst Biosciences (NASDAQ:CBIO)
Institutional Ownership by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ CBIO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2018James E FlynnInsiderSell71,778$30.53$2,191,382.34View SEC Filing  
3/6/2018James E FlynnMajor ShareholderSell52,461$30.87$1,619,471.07View SEC Filing  
12/17/2015Fletcher PayneCFOBuy10,000$2.00$20,000.00View SEC Filing  
12/17/2015Nassim UsmanCEOBuy4,000$2.00$8,000.00View SEC Filing  
12/17/2015Stephen A HillDirectorBuy5,000$2.03$10,150.0020,711View SEC Filing  
12/5/2013Scott Sandellmajor shareholderSell1,000$5.13$5,130.00View SEC Filing  
11/21/2013M James Barrettmajor shareholderSell5,333$5.16$27,518.28View SEC Filing  
5/10/2013Julia R BrownDirectorBuy6,000$5.09$30,540.00View SEC Filing  
3/11/2013Stephen A HillCEOBuy20,000$4.43$88,600.00View SEC Filing  
11/16/2012Bvf Partners L P/IlMajor ShareholderBuy595,000$4.00$2,380,000.00View SEC Filing  
11/8/2012Bvf Partners L P/IlMajor ShareholderBuy72,429$4.03$291,888.87View SEC Filing  
11/2/2012Bvf Partners L P/IlMajor ShareholderBuy139,700$4.05$565,785.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Catalyst Biosciences (NASDAQ CBIO) News Headlines

Source:
DateHeadline
3 Things In Biotech, April 14: Organovo, Catalyst, And Aeglea Open Up3 Things In Biotech, April 14: Organovo, Catalyst, And Aeglea Open Up
seekingalpha.com - April 15 at 9:05 AM
Initiation of Phase 2b Trial on Track for Q3 2018Initiation of Phase 2b Trial on Track for Q3 2018
globenewswire.com - April 12 at 8:25 AM
Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia BCatalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
finance.yahoo.com - April 12 at 8:25 AM
Catalyst Biosciences (CBIO) Downgraded to "Hold" at BidaskClubCatalyst Biosciences (CBIO) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 29 at 11:17 AM
Catalyst Biosciences Inc (CBIO) Given Average Rating of "Buy" by BrokeragesCatalyst Biosciences Inc (CBIO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 29 at 5:18 AM
Zacks: Analysts Set $57.00 Price Target for Catalyst Biosciences Inc (CBIO)Zacks: Analysts Set $57.00 Price Target for Catalyst Biosciences Inc (CBIO)
www.americanbankingnews.com - March 28 at 9:59 AM
Catalyst Biosciences (CBIO) Reports $1.5 MillionMilestone Payments for Neuronal Nicotinic Receptor (NNR) AssetCatalyst Biosciences (CBIO) Reports $1.5 MillionMilestone Payments for Neuronal Nicotinic Receptor (NNR) Asset
www.streetinsider.com - March 26 at 5:23 PM
Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) AssetCatalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) Asset
finance.yahoo.com - March 26 at 8:16 AM
Catalyst Biosciences (CBIO) Lifted to "Sell" at ValuEngineCatalyst Biosciences (CBIO) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 8:10 PM
Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference - GlobeNewswire (press release)Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 19 at 8:16 AM
Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare ConferenceCatalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference
finance.yahoo.com - March 19 at 8:16 AM
Financial Survey: Catalyst Biosciences (CBIO) versus Avid Bioservices (CDMO)Financial Survey: Catalyst Biosciences (CBIO) versus Avid Bioservices (CDMO)
www.americanbankingnews.com - March 12 at 9:14 PM
 Analysts Set $57.00 Target Price for Catalyst Biosciences Inc (CBIO) Analysts Set $57.00 Target Price for Catalyst Biosciences Inc (CBIO)
www.americanbankingnews.com - March 10 at 3:22 PM
Zacks.com featured highlights include: Unisys, Catalyst, Liberty and New MountainZacks.com featured highlights include: Unisys, Catalyst, Liberty and New Mountain
finance.yahoo.com - March 9 at 8:14 AM
Catalyst Biosciences Inc (CBIO) Major Shareholder Sells $1,619,471.07 in StockCatalyst Biosciences Inc (CBIO) Major Shareholder Sells $1,619,471.07 in Stock
www.americanbankingnews.com - March 8 at 6:13 PM
Catalyst Biosciences Inc (CBIO) Insider Sells $2,191,382.34 in StockCatalyst Biosciences Inc (CBIO) Insider Sells $2,191,382.34 in Stock
www.americanbankingnews.com - March 8 at 6:13 PM
Stock Traders Purchase High Volume of Put Options on Catalyst Biosciences (CBIO)Stock Traders Purchase High Volume of Put Options on Catalyst Biosciences (CBIO)
www.americanbankingnews.com - March 8 at 8:04 AM
Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:12 AM
Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care ConferenceCatalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 8:12 AM
Investors Purchase Large Volume of Call Options on Catalyst Biosciences (CBIO)Investors Purchase Large Volume of Call Options on Catalyst Biosciences (CBIO)
www.americanbankingnews.com - March 7 at 7:26 AM
Catalyst Biosciences (CBIO) & Mediwound (MDWD) Head-To-Head ComparisonCatalyst Biosciences (CBIO) & Mediwound (MDWD) Head-To-Head Comparison
www.americanbankingnews.com - March 4 at 1:10 AM
Analysts Anticipate Catalyst Biosciences Inc (CBIO) to Announce ($1.30) Earnings Per ShareAnalysts Anticipate Catalyst Biosciences Inc (CBIO) to Announce ($1.30) Earnings Per Share
www.americanbankingnews.com - March 2 at 7:12 PM
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2017 Operating & Financial Results and Provides Corporate UpdateCatalyst Biosciences Reports Fourth Quarter and Full-Year 2017 Operating & Financial Results and Provides Corporate Update
finance.yahoo.com - March 1 at 5:56 PM
Catalyst Biosciences (CBIO) Reports Manufacturing Agreement with AGC Biologics - StreetInsider.comCatalyst Biosciences (CBIO) Reports Manufacturing Agreement with AGC Biologics - StreetInsider.com
www.streetinsider.com - February 27 at 8:14 AM
Catalyst Biosciences (CBIO) Set to Announce Earnings on TuesdayCatalyst Biosciences (CBIO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:16 AM
Catalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679dCatalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679d
finance.yahoo.com - February 26 at 5:48 PM
Catalyst Biosciences Announces Closing of Public Offering of ... - GlobeNewswire (press release)Catalyst Biosciences Announces Closing of Public Offering of ... - GlobeNewswire (press release)
globenewswire.com - February 16 at 8:14 AM
 Catalyst Biosciences Inc (CBIO) Receives Average Rating of "Strong Buy" from Brokerages Catalyst Biosciences Inc (CBIO) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 14 at 7:18 PM
Catalyst Biosciences Inc (CBIO) to Post FY2017 Earnings of ($7.85) Per Share, B. Riley ForecastsCatalyst Biosciences Inc (CBIO) to Post FY2017 Earnings of ($7.85) Per Share, B. Riley Forecasts
www.americanbankingnews.com - February 14 at 6:10 AM
Catalyst Biosciences Inc Expected to Earn FY2022 Earnings of $2.70 Per Share (CBIO)Catalyst Biosciences Inc Expected to Earn FY2022 Earnings of $2.70 Per Share (CBIO)
www.americanbankingnews.com - February 13 at 4:52 PM
Catalyst Biosciences (CBIO) On Phase 1/2 clinical trial evaluating subcutaneous administration of hemophilia B candidate CB 2679d/ISU304 - SlideshowCatalyst Biosciences (CBIO) On Phase 1/2 clinical trial evaluating subcutaneous administration of hemophilia B candidate CB 2679d/ISU304 - Slideshow
seekingalpha.com - February 12 at 3:41 PM
 Analysts Set $36.08 Price Target for Catalyst Biosciences Inc (CBIO) Analysts Set $36.08 Price Target for Catalyst Biosciences Inc (CBIO)
www.americanbankingnews.com - February 10 at 9:34 PM
Chardan Capital Boosts Catalyst Biosciences (CBIO) Price Target to $75.00Chardan Capital Boosts Catalyst Biosciences (CBIO) Price Target to $75.00
www.americanbankingnews.com - February 10 at 1:26 PM
Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B ProductAnalyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product
finance.yahoo.com - February 10 at 9:10 AM
Catalyst Biosciences (CBIO) PT Set at $19.00 by B. RileyCatalyst Biosciences (CBIO) PT Set at $19.00 by B. Riley
www.americanbankingnews.com - February 9 at 9:30 PM
Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia BCatalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia B
finance.yahoo.com - February 9 at 9:21 AM
Catalyst Biosciences (CBIO) Given Buy Rating at B. RileyCatalyst Biosciences (CBIO) Given Buy Rating at B. Riley
www.americanbankingnews.com - February 1 at 2:54 PM
Catalyst Biosciences to Present Multi-Dose Subcutaneous Data for CB 2679d in Individuals with Hemophilia B in an Oral Presentation at the 11th Annual Congress of EAHADCatalyst Biosciences to Present Multi-Dose Subcutaneous Data for CB 2679d in Individuals with Hemophilia B in an Oral Presentation at the 11th Annual Congress of EAHAD
finance.yahoo.com - January 31 at 3:39 PM
Comparing Catalyst Biosciences (CBIO) and Cardiome Pharma (CRME)Comparing Catalyst Biosciences (CBIO) and Cardiome Pharma (CRME)
www.americanbankingnews.com - January 30 at 3:18 AM
 Catalyst Biosciences Inc (CBIO) Given Consensus Rating of "Strong Buy" by Brokerages Catalyst Biosciences Inc (CBIO) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 24 at 7:06 PM
 Brokerages Set $14.42 Target Price for Catalyst Biosciences Inc (CBIO) Brokerages Set $14.42 Target Price for Catalyst Biosciences Inc (CBIO)
www.americanbankingnews.com - January 8 at 10:06 PM
Catalyst Biosciences (CBIO) Commences Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia ... - StreetInsider.comCatalyst Biosciences (CBIO) Commences Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia ... - StreetInsider.com
www.streetinsider.com - January 5 at 9:18 AM
Catalyst Biosciences (CBIO) Commences Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with InhibitorsCatalyst Biosciences (CBIO) Commences Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors
www.streetinsider.com - January 4 at 5:35 PM
Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with InhibitorsCatalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors
finance.yahoo.com - January 4 at 9:11 AM
Catalyst Biosciences (CBIO) Rating Increased to Buy at Zacks Investment ResearchCatalyst Biosciences (CBIO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 2 at 10:34 PM
Zacks Investment Research Lowers Catalyst Biosciences (CBIO) to HoldZacks Investment Research Lowers Catalyst Biosciences (CBIO) to Hold
www.americanbankingnews.com - January 1 at 6:54 PM
Catalyst Biosciences Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)Catalyst Biosciences Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - December 23 at 6:08 AM
Catalyst Biosciences Announces Closing of Public Offering of Common StockCatalyst Biosciences Announces Closing of Public Offering of Common Stock
finance.yahoo.com - December 23 at 6:08 AM
Catalyst Biosciences Inc (NASDAQ:CBIO): Is Healthcare Attractive Relative To NasdaqCM Peers?Catalyst Biosciences Inc (NASDAQ:CBIO): Is Healthcare Attractive Relative To NasdaqCM Peers?
finance.yahoo.com - December 21 at 9:10 AM
Analysts Expect Catalyst Biosciences Inc (CBIO) to Post ($1.79) Earnings Per ShareAnalysts Expect Catalyst Biosciences Inc (CBIO) to Post ($1.79) Earnings Per Share
www.americanbankingnews.com - December 20 at 10:20 PM

SEC Filings

Catalyst Biosciences (NASDAQ:CBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Catalyst Biosciences (NASDAQ:CBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Catalyst Biosciences (NASDAQ CBIO) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.